Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy?

J. Brian Cassel, Egidio Del Fabbro, Tobias Arkenau, Irene J. Higginson, Samia Hurst, Lynn Jansen, Andrew Poklepovic, Annette Rid, Jordi Rodón, Florian Strasser, Franklin G. Miller

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

This article synthesizes the presentations and conclusions of an international symposium on Phase 1 oncology trials, palliative care, and ethics held in 2014. The purpose of the symposium was to discuss the intersection of three independent trends that unfolded in the past decade. First, large-scale reviews of hundreds of Phase I trials have indicated there is a relatively low risk of serious harm and some prospect of clinical benefit that can be meaningful to patients. Second, changes in the design and analysis of Phase I trials, the introduction of “targeted” investigational agents that are generally less toxic, and an increase in Phase I trials that combine two or more agents in a novel way have changed the conduct of these trials and decreased fears and apprehensions about participation. Third, the field of palliative care in cancer has expanded greatly, offering symptom management to late-stage cancer patients, and demonstrated that it is not mutually exclusive with disease-targeted therapies or clinical research. Opportunities for collaboration and further research at the intersection of Phase 1 oncology trials and palliative care are highlighted.

Original languageEnglish (US)
Pages (from-to)437-445
Number of pages9
JournalJournal of Pain and Symptom Management
Volume52
Issue number3
DOIs
StatePublished - Sep 1 2016

Fingerprint

Palliative Care
Neoplasms
Poisons
Research
Ethics
Fear
Therapeutics

Keywords

  • cancer
  • end-of-life care
  • ethics
  • informed consent
  • Palliative care
  • Phase I clinical trials

ASJC Scopus subject areas

  • Nursing(all)
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Phase I Cancer Trials and Palliative Care : Antagonism, Irrelevance, or Synergy? / Cassel, J. Brian; Del Fabbro, Egidio; Arkenau, Tobias; Higginson, Irene J.; Hurst, Samia; Jansen, Lynn; Poklepovic, Andrew; Rid, Annette; Rodón, Jordi; Strasser, Florian; Miller, Franklin G.

In: Journal of Pain and Symptom Management, Vol. 52, No. 3, 01.09.2016, p. 437-445.

Research output: Contribution to journalArticle

Cassel, JB, Del Fabbro, E, Arkenau, T, Higginson, IJ, Hurst, S, Jansen, L, Poklepovic, A, Rid, A, Rodón, J, Strasser, F & Miller, FG 2016, 'Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy?', Journal of Pain and Symptom Management, vol. 52, no. 3, pp. 437-445. https://doi.org/10.1016/j.jpainsymman.2016.02.014
Cassel, J. Brian ; Del Fabbro, Egidio ; Arkenau, Tobias ; Higginson, Irene J. ; Hurst, Samia ; Jansen, Lynn ; Poklepovic, Andrew ; Rid, Annette ; Rodón, Jordi ; Strasser, Florian ; Miller, Franklin G. / Phase I Cancer Trials and Palliative Care : Antagonism, Irrelevance, or Synergy?. In: Journal of Pain and Symptom Management. 2016 ; Vol. 52, No. 3. pp. 437-445.
@article{2278629e4626449b976b53e7fdc1adb1,
title = "Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy?",
abstract = "This article synthesizes the presentations and conclusions of an international symposium on Phase 1 oncology trials, palliative care, and ethics held in 2014. The purpose of the symposium was to discuss the intersection of three independent trends that unfolded in the past decade. First, large-scale reviews of hundreds of Phase I trials have indicated there is a relatively low risk of serious harm and some prospect of clinical benefit that can be meaningful to patients. Second, changes in the design and analysis of Phase I trials, the introduction of “targeted” investigational agents that are generally less toxic, and an increase in Phase I trials that combine two or more agents in a novel way have changed the conduct of these trials and decreased fears and apprehensions about participation. Third, the field of palliative care in cancer has expanded greatly, offering symptom management to late-stage cancer patients, and demonstrated that it is not mutually exclusive with disease-targeted therapies or clinical research. Opportunities for collaboration and further research at the intersection of Phase 1 oncology trials and palliative care are highlighted.",
keywords = "cancer, end-of-life care, ethics, informed consent, Palliative care, Phase I clinical trials",
author = "Cassel, {J. Brian} and {Del Fabbro}, Egidio and Tobias Arkenau and Higginson, {Irene J.} and Samia Hurst and Lynn Jansen and Andrew Poklepovic and Annette Rid and Jordi Rod{\'o}n and Florian Strasser and Miller, {Franklin G.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.jpainsymman.2016.02.014",
language = "English (US)",
volume = "52",
pages = "437--445",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Phase I Cancer Trials and Palliative Care

T2 - Antagonism, Irrelevance, or Synergy?

AU - Cassel, J. Brian

AU - Del Fabbro, Egidio

AU - Arkenau, Tobias

AU - Higginson, Irene J.

AU - Hurst, Samia

AU - Jansen, Lynn

AU - Poklepovic, Andrew

AU - Rid, Annette

AU - Rodón, Jordi

AU - Strasser, Florian

AU - Miller, Franklin G.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - This article synthesizes the presentations and conclusions of an international symposium on Phase 1 oncology trials, palliative care, and ethics held in 2014. The purpose of the symposium was to discuss the intersection of three independent trends that unfolded in the past decade. First, large-scale reviews of hundreds of Phase I trials have indicated there is a relatively low risk of serious harm and some prospect of clinical benefit that can be meaningful to patients. Second, changes in the design and analysis of Phase I trials, the introduction of “targeted” investigational agents that are generally less toxic, and an increase in Phase I trials that combine two or more agents in a novel way have changed the conduct of these trials and decreased fears and apprehensions about participation. Third, the field of palliative care in cancer has expanded greatly, offering symptom management to late-stage cancer patients, and demonstrated that it is not mutually exclusive with disease-targeted therapies or clinical research. Opportunities for collaboration and further research at the intersection of Phase 1 oncology trials and palliative care are highlighted.

AB - This article synthesizes the presentations and conclusions of an international symposium on Phase 1 oncology trials, palliative care, and ethics held in 2014. The purpose of the symposium was to discuss the intersection of three independent trends that unfolded in the past decade. First, large-scale reviews of hundreds of Phase I trials have indicated there is a relatively low risk of serious harm and some prospect of clinical benefit that can be meaningful to patients. Second, changes in the design and analysis of Phase I trials, the introduction of “targeted” investigational agents that are generally less toxic, and an increase in Phase I trials that combine two or more agents in a novel way have changed the conduct of these trials and decreased fears and apprehensions about participation. Third, the field of palliative care in cancer has expanded greatly, offering symptom management to late-stage cancer patients, and demonstrated that it is not mutually exclusive with disease-targeted therapies or clinical research. Opportunities for collaboration and further research at the intersection of Phase 1 oncology trials and palliative care are highlighted.

KW - cancer

KW - end-of-life care

KW - ethics

KW - informed consent

KW - Palliative care

KW - Phase I clinical trials

UR - http://www.scopus.com/inward/record.url?scp=84995705646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995705646&partnerID=8YFLogxK

U2 - 10.1016/j.jpainsymman.2016.02.014

DO - 10.1016/j.jpainsymman.2016.02.014

M3 - Article

C2 - 27233136

AN - SCOPUS:84995705646

VL - 52

SP - 437

EP - 445

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 3

ER -